Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities researchers at HC Wainwright cut their Q3 2025 EPS estimates for Krystal Biotech in a report released on Monday, August 4th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $1.06 per share for the quarter, down from their prior estimate of $1.58. HC Wainwright currently has a "Buy" rating and a $240.00 target price on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech's Q4 2025 earnings at $1.09 EPS, FY2025 earnings at $4.56 EPS, FY2026 earnings at $6.70 EPS, FY2027 earnings at $9.12 EPS and FY2028 earnings at $10.52 EPS.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million.
KRYS has been the subject of several other research reports. Bank of America dropped their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Chardan Capital reaffirmed a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a report on Tuesday. Guggenheim lowered their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Citigroup reaffirmed a "neutral" rating and set a $166.00 target price (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $210.22.
Check Out Our Latest Report on KRYS
Krystal Biotech Price Performance
KRYS stock opened at $136.00 on Thursday. The company has a 50 day moving average price of $141.24 and a 200 day moving average price of $155.67. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $207.84. The stock has a market capitalization of $3.93 billion, a PE ratio of 27.64 and a beta of 0.70.
Hedge Funds Weigh In On Krystal Biotech
Institutional investors and hedge funds have recently made changes to their positions in the company. Brooklyn Investment Group lifted its position in Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after acquiring an additional 105 shares in the last quarter. Hantz Financial Services Inc. lifted its position in Krystal Biotech by 8,950.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock valued at $25,000 after acquiring an additional 179 shares in the last quarter. Twin Tree Management LP bought a new stake in Krystal Biotech in the 1st quarter valued at $29,000. Fifth Third Bancorp lifted its position in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after acquiring an additional 105 shares in the last quarter. Finally, First Horizon Advisors Inc. lifted its position in Krystal Biotech by 212.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company's stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.
Insider Activity
In other news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the transaction, the insider owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. The trade was a 0.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is owned by insiders.
Krystal Biotech Company Profile
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.